Frequency and significance of phenotypes for α1-antitrypsin deficiency in type 1 autoimmune hepatitis

Digestive Diseases and Sciences

Volumn 43, Issue 8, 1998, Pages 1725-1731

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Phenotypes; 1 antitrypsin deficiency

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; PREDNISONE;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; FEMALE; GENE FREQUENCY; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031828134     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018875401612     Document Type: Article

References (40)

1. Feld RD: Heterozygosity of alpha 1-antitrypsin: A health risk? Crit Rev Clin Lab Sci 27:461-481, 1989
2. Hood JM, Koep LJ, Peters RL, Schroter GPJ, Weil R III, Redeker AG, Starzyl TE: Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N Engl J Med 302:272-275, 1986
3. Triger DR, Millward-Sadler GH, Czaykowski AA, Trowell J, Wright R: Alpha-1-antitrypsin deficiency and liver disease in adults. Q J Med 45:351-372, 1976
4. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W: Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol 21:1006-1011, 1994
5. Elzouki AN, Eriksson S: Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): Is chronic viral hepatitis B or C an additional risk factor lor cirrhosis and hepatocellular carcinoma? Eur J Gastroent Hepatol 8:989-994, 1996
6. Bartmann K, Fooke-Achterrath M, Koch G, Nagy I, Schutz I, Weis E, Zierski M: Heterozygosity in the Pi-system as a pathogenic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Respir Pis 66:284-296, 1985
7. Lieberman J, Winter B, Sastre A: Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 89:370-373, 1986
8. Hodges JR, Millward-Sadler GH, Barbatis C, Wright R: Heterozygous MZ alpha-1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 304:557-560, 1981
9. Eriksson S: Liver disease and intermediate alpha-1-antitrypsin deficiency. Acta Med Scand 210:241-244, 1981
10. McDonagh DJ, Nathan SP, Knudson RJ, Lebowitz MD: Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison adult normal and heterozygous protease inhibitor phenotype subjects from a random population. J Clin Invest 63:299-309, 1979
11. Gerblich AA, Kleinerman J, Rynbrandt DJ, Chester EH, Ihrig J: Pi-Z phenotypes in a pulmonary clinic. Their prevalence and physiologic state. Am J Clin Pathol 69:509-513, 1978
12. Fisher RL, Taylor L, Sherlock S: Alpha-1-antitrypsin deficiency in liver disease: The extent of the problem. Gastroenterology 71:646-651, 1976
13. Vecchio FM, Fabiano A, Orsini G, Ragusa D, Massi G: Alpha-1-antitrypsin MZ phenotype and cryptogenic chronic liver disease in adults. Digestion 27:100-104, 1983
14. Cox DW, Huber O: Association of severe rheumatoid arthritis with heterozygosity for alpha 1-antitrypsin deficiency. Clin Genet 17:153-160, 1980
15. Rakela J, Goldschmiedt M, Ludwig J: Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci 32:1358-1362, 1987
16. 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol 92:602-607, 1997
17. Czaja AJ, Davis GL, Ludwig J, Taswell HF: Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4:622-627, 1984
18. Czaja AJ, Ammon HV, Summerskill WHJ: Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 78:518-523, 1980
19. Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R: Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3:685-689, 1983
20. Czaja AJ, Beaver SJ, Shiels MT: Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 92:215-219, 1987
21. Davis GL, Czaja AJ, Ludwig J: Development and prognosis of histologie cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 87:1222-1227, 1984
22. Roberts SK, Therneau T, Czaja AJ: Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110:848-857, 1996
23. Wang KK, Czaja AJ: Hepatocellular cancer in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology 8:1679-1683, 1988
24. Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, Czaja AJ, Desmet V, Edleston ALWF, Gerber MA, Hoofnagle JH, Kakumu S, MacSween RNM, Maddrey WC, Manns MP, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Portmann BC, Reed WD, Schalm SW, Scheuer PJ, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: Meeting report. International Autoimmune Hepatitis Group. Hepatology 18:998-1005, 1993
25. Czaja AJ, Manns MP: The validity and importance of subtypes of autoimmune hepatitis: A point of view. Am J Gastroenterol 90:1206-1211, 1995
26. Kueppers F, Christopherson MJ: Alpha-1-antitrypsin: Further genetic heterogeneity revealed by isoelectric focusing. Am J Hum Genet 30:359-365, 1978
27. Czaja AJ: Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis. In Autoimmune Liver Disease. EL Krawitt, RH Wiesner (eds). New York, Raven Press, 1991, pp 143-166
28. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH: Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16:876-883, 1975
29. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 24:52-59, 1996
30. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB: Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24:1068-1073, 1996
31. Czaja AJ, Manns MP, Homburger HA: Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290-1295, 1992
32. Kueppers F: Determination of alpha-1-antitrypsin phenotypes by isoelectric focusing in polyacrylamide gels. J Lab Clin Med 88:151-155, 1976
33. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 126:137-145, 1997
34. Czaja AJ, Carpenter HA, Santraeh PJ, Moore SB, Homburger HA: The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 104:1755-1761, 1993
35. Hall P, Herrmann R, Brennan J, Mackinnon M: Detection of alpha-1-antitrypsin in hepatocytes in acute and chronic hepatitis. Pathology 19:415-418, 1987
36. Czaja AJ, Carpenter HA, Santraeh PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816-822, 1993
37. Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA: A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DO alleles, including Drw10. Transplantation 45:640-646, 1988
38. Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225-235, 1992
39. Strettell MDJ, Donaldson PT, Thomson LJ, Santraeh PJ, Moore SB, Czaja AJ, Williams R: Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112:2028-2035, 1997
40. Callea F, Fevery J, De Groote J, Desmet VJ: Detection of Pi Z phenotype individuals by alpha-1-antitrypsin (AAT) immunohistochemistry in paraffin-embedded liver tissue specimens. J Hepatol 2:389-401, 1986